Applicant: Bal Ram Singh et al. Attorney's Docket No.: 08387-002003

Serial No.: Not Yet Assigned

Filed: Herewith Page: 3 of 6

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Original) A substantially pure polypeptide complex comprising a Clostridium botulinium neurotoxin and more than one Clostridium botulinium type E neurotoxin associated polypeptide.

2-6. (Canceled)

7. (Original) A substantially pure Clostridium botulinium serotype E neurotoxin associated polypeptide.

8-16. (Canceled)

- 17. (Original) A substantially pure antibody that specifically binds to a Clostridium botulinum type E neurotoxin associated polypeptide having a molecular weight of approximately 80, 60, 45, or 18 kDa, or to a complex of any two or more of said neurotoxin associated polypeptides.
- 18. (Original) A substantially pure antibody that specifically binds to a polypeptide complex of claim 1.
- 19. (Original) A method of detecting a serotype E neurotoxin complex in a sample, the method comprising:
 - (a) contacting the sample with an antibody of claim 17, and

Applicant: Bal Ram Singh et al. Attorney's Docket No.: 08387-002003

Serial No.: Not Yet Assigned

Filed: Herewith Page: 4 of 6

(b) detecting antibody-bound polypeptide, if any, in the sample, the presence of antibody-bound polypeptide indicating the presence of serotype E neurotoxin in the sample.

- 20. (Original) The method of claim 19, wherein the sample is a foodstuff.
- 21. (Original) The method of claim 19, wherein the sample is a gastrointestinal, blood, or tissue sample obtained from a vertebrate animal.
- 22. (Original) A method of treating a patient who is suffering from a disease or condition associated with excessive release of acetylcholine from presynaptic nerve terminals, the method comprising administering to the patient a therapeutically effective amount of a polypeptide complex of claim 1.
- 23. (Original) The method of claim 22, wherein the excessive acetylcholine release causes undesirable contraction of smooth or skeletal muscle cells.
- 24. (Original) The method of claim 22, wherein the excessive release of acetylcholine causes profuse sweating, lacrimation, or mucous secretion.
- 25. (Original) A method of treating a patient who is suffering from spasticity occurring secondary to brain ischemia, or traumatic injury of the brain or spinal cord, the method comprising administering to the patient a therapeutically effective amount of a polypeptide complex of claim 1.
- 26. (Original) A method of treating a patient who is suffering from tension headache or pain, the method comprising administering to the patient a therapeutically effective amount of a polypeptide complex of claim 1.

Applicant: Bal Ram Singh et al. Attorney's Docket No.: 08387-002003

Serial No.: Not Yet Assigned

Filed : Herewith Page : 5 of 6

27-29. (Canceled)

30. (Original) A method of detecting a Clostridium botulinum serotype E neurotoxin in a sample, the method comprising:

- (a) contacting the sample with a Clostridium botulinum type E neurotoxin associated polypeptide (NAP) of claim 7 that specifically binds a serotype E botulinum neurotoxin and thereby forms a NAP-neurotoxin complex, and
- (b) detecting the NAP-neurotoxin complex, if any, in the sample, the presence of a complex indicating the presence of serotype E neurotoxin in the sample.

31-32. (Canceled)